Heart failure & cardiomyopathies
Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial
Authors' conclusion
Among patients with HFpEF/HFmrEF in FINEARTS-HF, higher baseline HR was associated with a higher risk of the primary outcome in patients with SR but not in those with AF. Finerenone's effect on the primary outcome was consistent across the HR spectrum, irrespective of rhythm.
Study context
- Population
- Patients with HFmrEF/HFpEF in FINEARTS-HF, by baseline ECG rhythm (sinus rhythm or atrial fibrillation (AF)); pacemaker rhythm or missing HR/rhythm data excludedSR n = 3497
- Comparison
- Finerenone vs placebo, across baseline HR by heart rhythm
- Primary endpoint
- Composite of:
- CV death
- Total (first and recurrent) HF events
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
Baseline HR and primary outcome, and finerenone effect across HR spectrum, by rhythm (subgroups)
- Finerenone effect on primary outcome consistent across HR spectrum in SR
- P for interaction = 0.96
- Finerenone effect on primary outcome consistent across HR spectrum in AF
- P for interaction = 0.49
Further findings
| Outcome | Placebo-corrected decrease (bpm) (95% CI) |
|---|---|
| HR change, AF · baseline to 12 months | 1.35 (0.41–2.29) |
HR change, SR
- No significant HR change with finerenone vs placebo
Original publication
Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial. Eur J Heart Fail. Published 14 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →